Ambulatory patient with signs of heart failure (HF) and a history of hospitalisation due to HF exacerbation Case report
Article Sidebar
Published:
Jun 30, 2015
Keywords:
heart failure, exercise tolerance, ivabradine, exacerbation, hospitalisation
Main Article Content
Abstract
Symptoms limiting daily physical activity among patients with heart failure (HF) result in quality of life. Proceedings according to the guidelines for patients with HF increase the length of survival, reduce the risk of subsequent hospitalization and the severity of symptoms. The therapy of heart failure supplemented with ivabradine improves the functional capacity and quality of life while reducing the risk of subsequent hospital admissions. It may result in prognosis improving especially in the case of a patient who has already had past hospitalizations secondary to worsening of symptoms.
Article Details
How to Cite
Balsam , P. (2015). Ambulatory patient with signs of heart failure (HF) and a history of hospitalisation due to HF exacerbation. Medycyna Faktow (J EBM), 8(2(27), 16-19. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2305
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. McMurray J.J., Adamopoulos S., Anker S.D. et al.: ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. European Heart Journal 2012; 33(14): 1787-1847.
2. Swedberg K., Komajda M., Bohm M. et al.: Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376(9744): 875-885.
3. Setoguchi S., Stevenson L.W., Schneeweiss S.: Repeated hospitalizations predict mortality in the community population with heart failure. American Heart Journal 2007; 154(2): 260-266.
4. Bagriy A.E., Schukina E.V., Samoilova O.V. et al.: Addition of ivabradine to β-blocker improves exercise capacity in systolic heart failure patients in a prospective, open-label study. Advances in Therapy 2015; 32(2): 108-119.
2. Swedberg K., Komajda M., Bohm M. et al.: Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376(9744): 875-885.
3. Setoguchi S., Stevenson L.W., Schneeweiss S.: Repeated hospitalizations predict mortality in the community population with heart failure. American Heart Journal 2007; 154(2): 260-266.
4. Bagriy A.E., Schukina E.V., Samoilova O.V. et al.: Addition of ivabradine to β-blocker improves exercise capacity in systolic heart failure patients in a prospective, open-label study. Advances in Therapy 2015; 32(2): 108-119.